Search Results - "Fernández Román, AB"

4CPS-055 Effectiveness and safety of ribociclib in the first line of luminal metastatic breast cancer by Canalejo Fuentes, MJ, Fernández Román, AB, Candel García, B, Letéllez Fernández, J, García Gil, M

“…Background and ImportanceRibociclib is a cyclin-dependent kinase inhibitor used in the first line of luminal metastatic breast cancer (MBC).Aim and…”
Get full text

1ISG-010 Pharmacy staff satisfaction and opinion of new website application for outpatient care by Merino, A, Herrero Muñoz, N, Fernández Román, AB, Hernández Muniesa, B, Pou Alonso, A, Ontañón Nasarre, A, Pedreira Bouzas, J, Canalejo Fuentes, MJ, García Gil, M

“…Background and ImportanceUp until March 2022, medical prescription orders and next appointments were printed on paper for pharmaceutical validation and…”
Get full text

DI-095 Possible severe eosinophilia induced by dimethyl fumarate in relapsing remitting multiple sclerosis by Román, AB Fernández, Nasarre, A Ontañón, Alonso, A Pou, Rosado, A Andrés, López, C Mayo, Muñoz, N Herrero, Gomez, F, Gil, M García

“…BackgroundDimethyl fumarate (DMF) is prescribed for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS). Although mild to…”
Get full text

PS-059 Aripiprazole induced dysphagia: A case report by Rosado, A Andres, Clemente, Y Castellanos, López, C Mayo, Román, AB Fernández, Muñoz, N Herrero, Gil, M Garcia

“…BackgroundDysphagia is an uncommon adverse reaction caused by psychotropic drugs. It is a principal manifestation of extrapyramidal symptoms and the main…”
Get full text

1ISG-019 A cost-effectiveness analysis of biological therapies for moderate to severe psoriasis by Rosado, A Andres, Román, AB Fernández, Muñoz, N Herrero, Gil, M García

“…BackgroundBiological therapies (BT) have been a breakthrough in the treatment of psoriasis. Compared to conventional therapies, biologics are more effective…”
Get full text

1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting by Román, AB Fernández, Lázaro, C Bravo, Fernández, J Letellez, Muñoz, N Herrero, Rosado, A Andrés, Lopez, C Mayo, Gutierrez, MDM Garcia, Gil, M Garcia

“…BackgroundNivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to…”
Get full text

4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017 by Muñoz, N Herrero, Rosado, A Andrés, Muniesa, B Hernández, Lázaro, C Bravo, Román, AB Fernández, Alonso, A Pou, Nasarre, A Ontañón, Gutiérrez, MDM García, López, C Mayo, Gil, M García

“…BackgroundAdalimumab is a monoclonal antibody indicated in immunomediate inflammatory diseases for subcutaneous administration by two different devices:…”
Get full text

4CPS-219 Analysis of pharmaceutical interventions in an emergency department by Fernandez Roman, AB, Mariño Martinez, C, Martin Lopez, M, Herrero Muñoz, N, Garcia Gutierrez, MDM, Garcia Gil, M

“…BackgroundMedication errors in the emergency department can persist throughout the episode of care and up to hospital discharge, leading to inadequate…”
Get full text

PS-053 Severe thrombocytopenia induced by regorafenib in a metastatic colon cancer patient: A case report by Carmen, ML, Fernández, J Letéllez, Clemente, Y Castellanos, Rosado, A Andrés, Román, AB Fernandez, García, B Candel, Gil, M García

“…BackgroundRegorafenib is the third line of treatment used in metastatic colon cancer. One of the most frequent adverse effects of regorafenib is…”
Get full text